Human mesenchymal stein cells alleviate bleomycin-induced pulmonary fibrosis in humanized mice

Ke Ni,Ming Liu,Jian Zheng,Liyan Wen,Qingyun Chen,Zheng Xiang,Kowk-Tai Lam,Yinping Liu,Godfrey Chi-Fung Chan,Yu-Lung Lau,Wenwei Tu
DOI: https://doi.org/10.4049/jimmunol.198.supp.82.21
2017-01-01
Abstract:Abstract Pulmonary fibrosis is a chronic disease characterized by progressive pulmonary function disruption and activity limitation, of which the pathogenesis and the effective therapy have not been elucidated. Although aberrant immune cell infiltration was found in the lung of patients with pulmonary fibrosis, the contribution of immune dysregulation in pulmonary fibrosis has not been confirmed in human. In order to directly investigate the role human immune response in pulmonary fibrosis in vivo, human periphery blood mononuclear cells (PBMC)-reconstituted humanized mice were used to establish bleomycin-induced pulmonary fibrosis model in this study. In addition, the suppressive efficacy of human bone marrow-derived mesenchymal stem cells (MSC) on pulmonary fibrosis were also evaluated based on this model. Here we found the abnormal activity of the human immune response in the lung prior to pulmonary fibrosis. Human MSC administration at the early stage could significantly modulate pulmonary human immune dysregulation, alleviate pulmonary damage, and improve lung function in humanized mice with pulmonary fibrosis. Furthermore, PD-L1 and indoleamine 2, 3-dioxygenase (IDO) were found to be involved in the immunomodulatory effect of human MSC on pulmonary fibrosis in humanized mice. This study demonstrates the relationship between human immune dysregulation and pulmonary fibrosis in humanized mice. It also suggests the therapeutic efficacy of human MSC for pulmonary fibrosis.
What problem does this paper attempt to address?